Exclusive special offer and discount title banner vector image

ASIA-PACIFIC BOTULINUM TOXIN MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

Asia-Pacific Botulinum Toxin Market by Type (Type A Botulinum Toxin, Type B Botulinum Toxin) Market by User Demographic (Women, Men) Market by Application (Medical (Chronic Migraine, Muscle Spasm, Overactive Bladder, Hyperhidrosis, Other Medical Applications), Aesthetic (Crow’s Feet, Forehead Lines, Frown Lines/glabellar, Square Jaw/masseter, Other Aesthetic Applications)) Market by End-user (Specialty and Dermatology Clinics, Hospitals and Clinics, Other End-users) by Geography


MARKET OVERVIEW

The Asia-Pacific botulinum toxin market is set to generate $2589.71 million by 2032, propelling at a 10.19% CAGR during the estimated years between 2023-2032.

Botulinum toxin type A continues to be the most sought-after non-surgical aesthetic treatment in the Asia-Pacific region, as an increasing number of women aim to alter their inherent features. The botulinum toxin market experiences growth due to the rising preference for facial morphology modifications and the pursuit of geographically and culturally ideal beauty standards.

Botulinum toxin treatments are popular among facelift patients, as they offer minimal discomfort, reduced downtime, and lasting effects. Dysport (botulinum toxin) has garnered positive feedback for its patient tolerance, low side effects, and the possibility of multiple annual administrations for optimal outcomes. These factors are expected to boost the sales of botulinum toxin treatments in the forecasted period.

To Know More About This Report, Request a Free Sample Copy

The Asia-Pacific botulinum toxin market growth analysis entails the evaluation of South Korea, Thailand, Singapore, Australia & New Zealand, China, Japan, India, and Rest of Asia-Pacific. Japan boasts a well-developed healthcare system, with most specialists practicing medicine under national healthcare. Increasingly, younger dermatologists explore uninsured aesthetic treatments. In 2019, the International Society of Aesthetic Plastic Surgery reported 465,479 filler treatments in Japan, including 337,579 botulinum procedures and 126,921 hyaluronic filler procedures. Botulinum filler operations account for 27.6% of all minimally invasive procedures in the country. 

On the other hand, using toxins in facial beautification is an emerging field in India. The rapid growth of India’s aesthetic industry reflects increased public awareness of such treatments. The male-to-female ratio for aesthetic procedures is currently 1:1. The International Society of Aesthetic Plastic Surgery stated that in 2019, approximately 113,616 injectable procedures were performed in India, including about 42,552 hyaluronic acid injections and 70,248 botulinum toxin procedures.

The Asia-Pacific botulinum toxin market segmentation assessment includes application, type, end-user, and user demographic. Market by type covers type A botulinum toxin and type B botulinum toxin.

Botulinum toxin type A is a potent neurotoxin protein derived from the bacteria Clostridium Botulinum and is one of the most powerful toxins known to man. This toxin is frequently associated with systemic botulism in humans and is known to block neuromuscular transmission by binding to the acceptor sites of motor or sympathetic nerve terminals and inhibiting acetylcholine release. Originally used to treat ‘crossed eyes,’ this toxin gained immense importance for cosmetic purposes and is now widely used for treating wrinkles on the face caused by habitual facial muscle contractions.

The botulinum toxin type A injections market is expected to grow significantly as more companies introduce new products. In September 2019, Ipsen Biopharmaceuticals received United States FDA approval for Dysport (abobotulinumtoxinA) to treat upper limb spasticity for pediatric patients aged two years and above. Furthermore, according to the Plastic Surgery Statistics Report’s data, approximately 7.7 million minimally invasive procedures of botulinum toxin type A injections were performed in the United States in 2019, representing a 4% increase compared to 2018. The growing use of botulinum toxin type A for medical and cosmetic purposes is expected to drive demand for these injections.

Key players operating in the Asia-Pacific botulinum toxin market include Daewoong Pharmaceutical Co Ltd, Lanzhou Institute of Biological Products Co Ltd, etc.

Daewoong Pharmaceutical Co Ltd, a subsidiary of Daewoong Co Ltd, is a South Korean manufacturer and distributor of APIs, quasi-drugs, prescription drugs, and healthcare products. The company produces diverse products, including injections, ointments, tablets, liquids, sprays, and capsules catering to various medical needs such as respiratory system remedies, bone and joint diseases, central nervous system diseases, gastrointestinal diseases, cardiovascular diseases, dermatological diseases, and circulatory system diseases. 

In addition to product manufacturing, Daewoong Pharmaceutical engages in product development and commercialization through in-licensing, co-marketing, and co-promotion. The company has a global presence in Thailand, Israel, Canada, Germany, India, Vietnam, Indonesia, Switzerland, China, the United States, and Japan, with headquarters in Seoul, South Korea.

Daewoong Pharmaceutical’s Toxin Type A (Nabota) is a prescription medicine used for the correction of strabismus in patients aged 12 years or older, blepharospasm associated with dystonia, management of focal spasticity, and temporary improvement in the appearance of upper facial rhytides (including forehead lines, crow’s feet, and glabellar lines) in adults.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments Analyzed
Type, User Demographic, Application, and End-User
Countries AnalyzedChina, Japan, India, South Korea, Singapore, Thailand, Australia & New Zealand, and Rest of Asia-Pacific
Companies Analyzed

AbbVie Inc, Candela Medical, Daewoong Pharmaceutical Co Ltd, Evolus Inc, Galderma, Hugel Inc, Ipsen, Lanzhou Institute of Biological Products Co Ltd, Medytox, Merz Pharma, Revance Therapeutics Inc, US WorldMeds LLC

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
      1. IMPACT OF COVID-19 ON BOTULINUM TOXIN MARKET
    5. MAJOR MARKET FINDINGS
      1. FAVORABLE REGULATORY APPROVALS ADD TO MARKET GROWTH
      2. GROWING AWARENESS ABOUT ‘NOTOX’
      3. INFLATING COSMETIC TOURISM ADDS TO THE DEMAND FOR BOTULINUM TOXIN
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. SURGE IN DEMAND FOR AESTHETIC PROCEDURES
      2. RISING GERIATRIC POPULATION
      3. GROWING DEMAND FOR NON-INVASIVE COSMETIC PROCEDURES 
    2. KEY RESTRAINTS
      1. CONCERNS REGARDING THE ADVERSE EFFECTS OF BOTULINUM TOXIN
      2. LACK OF REIMBURSEMENT POLICIES SUPPORTING COSMETIC PROCEDURES
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
    2. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    3. GROWTH PROSPECT MAPPING
      1. GROWTH PROSPECT MAPPING FOR CHINA
    4. MARKET MATURITY ANALYSIS
    5. MARKET CONCENTRATION ANALYSIS
  5. MARKET BY TYPE
    1. TYPE A BOTULINUM TOXIN
    2. TYPE B BOTULINUM TOXIN
  6. MARKET BY USER DEMOGRAPHIC
    1. WOMEN
    2. MEN
  7. MARKET BY APPLICATION
    1. MEDICAL
      1. CHRONIC MIGRAINE
      2. MUSCLE SPASM
      3. OVERACTIVE BLADDER
      4. HYPERHIDROSIS
      5. OTHER MEDICAL APPLICATIONS
    2. AESTHETIC
      1. CROW’S FEET
      2. FOREHEAD LINES
      3. FROWN LINES/GLABELLAR
      4. SQUARE JAW/MASSETER
      5. OTHER AESTHETIC APPLICATIONS
  8. MARKET BY END-USER
    1. SPECIALTY AND DERMATOLOGY CLINICS
    2. HOSPITALS AND CLINICS
    3. OTHER END-USERS
  9. GEOGRAPHICAL ANALYSIS
    1. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC BOTULINUM TOXIN MARKET DRIVERS
      3. ASIA-PACIFIC BOTULINUM TOXIN MARKET CHALLENGES
      4. ASIA-PACIFIC BOTULINUM TOXIN MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN ASIA-PACIFIC BOTULINUM TOXIN MARKET
      6. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
        5. SINGAPORE
          1. SINGAPORE BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
        6. THAILAND
          1. THAILAND BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
        7. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
        8. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
  10. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS
      4. BUSINESS EXPANSIONS
    2. COMPANY PROFILES
      1. ABBVIE
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      2. CANDELA MEDICAL
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      3. DAEWOONG PHARMACEUTICAL CO LTD
        1. COMPANY PROFILE
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      4. EVOLUS INC
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      5. GALDERMA
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      6. HUGEL INC
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      7. IPSEN
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      8. LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO LTD
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      9. MEDYTOX INC
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      10. MERZ PHARMA
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      11. REVANCE THERAPEUTICS INC
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
      12. US WORLDMEDS LLC
        1. COMPANY OVERVIEW
        2. PRODUCT LIST

LIST OF TABLES

TABLE 1: ASIA-PACIFIC MARKET SNAPSHOT – BOTULINUM TOXIN

TABLE 2: EXAMPLE OF COMMERCIALLY AVAILABLE BOTULINUM TOXIN TYPE A FOR AESTHETIC PROCEDURES

TABLE 3: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 4: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY TYPE, FORECAST YEARS 2023-2032 (IN $ MILLION)

TABLE 5: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY USER DEMOGRAPHIC, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 6: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY USER DEMOGRAPHIC, FORECAST YEARS 2023-2032 (IN $ MILLION)

TABLE 7: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY APPLICATION, FORECAST YEARS 2023-2032 (IN $ MILLION)

TABLE 9: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY MEDICAL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 10: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY MEDICAL, FORECAST YEARS 2023-2032 (IN $ MILLION)

TABLE 11: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY AESTHETIC, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 12: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY AESTHETIC, FORECAST YEARS 2023-2032 (IN $ MILLION)

TABLE 13: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY END-USER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 14: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY END-USER, FORECAST YEARS 2023-2032 (IN $ MILLION)

TABLE 15: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 16: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 17: ASIA-PACIFIC BOTULINUM TOXIN MARKET REGULATORY FRAMEWORK

TABLE 18: KEY PLAYERS OPERATING IN ASIA-PACIFIC BOTULINUM TOXIN MARKET

TABLE 19: LIST OF ACQUISITIONS

TABLE 20: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 21: LIST OF PARTNERSHIPS 

TABLE 22: LIST OF BUSINESS EXPANSIONS

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR CHINA

FIGURE 4: MARKET MATURITY ANALYSIS

FIGURE 5: MARKET CONCENTRATION ANALYSIS

FIGURE 6: ASIA-PACIFIC BOTULINUM TOXIN MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022

FIGURE 7: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY TYPE A BOTULINUM TOXIN, 2023-2032 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY TYPE B BOTULINUM TOXIN, 2023-2032 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC BOTULINUM TOXIN MARKET, GROWTH POTENTIAL, BY USER DEMOGRAPHIC, IN 2022

FIGURE 10: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY WOMEN, 2023-2032 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY MEN, 2023-2032 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC BOTULINUM TOXIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2022

FIGURE 13: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY MEDICAL, 2023-2032 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC BOTULINUM TOXIN MARKET, GROWTH POTENTIAL, BY MEDICAL, IN 2022

FIGURE 15: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY CHRONIC MIGRAINE, 2023-2032 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY MUSCLE SPASM, 2023-2032 (IN $ MILLION)

FIGURE 17: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY OVERACTIVE BLADDER, 2023-2032 (IN $ MILLION)

FIGURE 18: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY HYPERHIDROSIS, 2023-2032 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY OTHER MEDICAL APPLICATIONS, 2023-2032 (IN $ MILLION)

FIGURE 20: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY AESTHETIC, 2023-2032 (IN $ MILLION)

FIGURE 21: ASIA-PACIFIC BOTULINUM TOXIN MARKET, GROWTH POTENTIAL, BY AESTHETIC, IN 2022

FIGURE 22: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY CROW’S FEET, 2023-2032 (IN $ MILLION)

FIGURE 23: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY FOREHEAD LINES, 2023-2032 (IN $ MILLION)

FIGURE 24: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY FROWN LINES/GLABELLAR, 2023-2032 (IN $ MILLION)

FIGURE 25: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY SQUARE JAW/MASSETER, 2023-2032 (IN $ MILLION)

FIGURE 26: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY OTHER AESTHETIC APPLICATIONS, 2023-2032 (IN $ MILLION)

FIGURE 27: ASIA-PACIFIC BOTULINUM TOXIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2022

FIGURE 28: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY SPECIALTY AND DERMATOLOGY CLINICS, 2023-2032 (IN $ MILLION)

FIGURE 29: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY HOSPITALS AND CLINICS, 2023-2032 (IN $ MILLION)

FIGURE 30: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY OTHER END-USERS, 2023-2032 (IN $ MILLION)

FIGURE 31: ASIA-PACIFIC BOTULINUM TOXIN MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN%)

FIGURE 32: CHINA BOTULINUM TOXIN MARKET, 2023-2032 (IN $ MILLION)

FIGURE 33: JAPAN BOTULINUM TOXIN MARKET, 2023-2032 (IN $ MILLION)

FIGURE 34: INDIA BOTULINUM TOXIN MARKET, 2023-2032 (IN $ MILLION)

FIGURE 35: SOUTH KOREA BOTULINUM TOXIN MARKET, 2023-2032 (IN $ MILLION)

FIGURE 36: SINGAPORE BOTULINUM TOXIN MARKET, 2023-2032 (IN $ MILLION)

FIGURE 37: THAILAND BOTULINUM TOXIN MARKET, 2023-2032 (IN $ MILLION)

FIGURE 38: AUSTRALIA & NEW ZEALAND BOTULINUM TOXIN MARKET, 2023-2032 (IN $ MILLION)

FIGURE 39: REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET, 2023-2032 (IN $ MILLION)

FAQ’s